{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:57:19Z","timestamp":1784793439175,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40259-023-00601-w","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T09:02:17Z","timestamp":1683363737000},"page":"675-684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a\u00a0Real-World Setting: A Nationwide Study from England and Italy"],"prefix":"10.1007","volume":"37","author":[{"given":"Francesco","family":"Ciccimarra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Luxi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bellitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"L\u2019 Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"De Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Savoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Yeomans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Molokhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Tacconelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-7296","authenticated-orcid":false,"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"key":"601_CR1","unstructured":"Centre for Disease Control and Prevention (CDC). CDC Museum COVID-19 Timeline. 2023. Accessed March 6, 2023. Available from: https:\/\/www.cdc.gov\/museum\/timeline\/covid19.html."},{"key":"601_CR2","unstructured":"World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. 2023. Accessed March 6, 2023. Available from: https:\/\/covid19.who.int."},{"key":"601_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.588654","volume":"11","author":"J Sultana","year":"2020","unstructured":"Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifir\u00f2 G. Challenges for drug repurposing in the COVID-19 pandemic era. Front Pharmacol. 2020;11: 588654. https:\/\/doi.org\/10.3389\/fphar.2020.588654.","journal-title":"Front Pharmacol."},{"key":"601_CR4","unstructured":"European Medicines Agency. COVID-19 treatments. 2023. Accessed March 6, 2023. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/covid-19-treatments."},{"key":"601_CR5","unstructured":"Italian Medicines Agency (AIFA). Use of oral antivirals for COVID-19. 2023. Accessed March 6, 2023. Available from: https:\/\/www.aifa.gov.it\/en\/uso-degli-antivirali-orali-per-covid-19."},{"key":"601_CR6","unstructured":"Italian Medicines Agency (AIFA). Use of monoclonal antibodies for COVID-19. 2023. Accessed March 6, 2023. Available from: https:\/\/www.aifa.gov.it\/en\/uso-degli-anticorpi-monoclonali."},{"key":"601_CR7","unstructured":"UK Parliament. Drug Therapies for COVID-19. 2023. Accessed March 6, 2023. Available from: https:\/\/post.parliament.uk\/drug-therapies-for-covid-19\/."},{"key":"601_CR8","unstructured":"European Medicines Agency (EMA). Refusal of the marketing authorisation for Lagevrio (molnupiravir). 2023. Accessed March 6, 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/questions-answers-refusal-marketing-authorisation-lagevrio-molnupiravir_en.pdf."},{"key":"601_CR9","unstructured":"European Medicines Agency (EMA). ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2. 2022. Accessed March 6, 2023. Available from: https:\/\/www.ema.europa.eu\/en\/news\/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2#:~:text=Contacts-,ETF%20warns%20that%20monoclonal%20antibodies%20may%20not%20be%20effective,strains%20of%20SARS%2DCoV%2D2&text=EMA's%20Emergency%20Task%20Force%20(ETF,of%20SARS%2DCoV%2D2."},{"key":"601_CR10","unstructured":"National Health Service (NHS) England. COVID-19 Therapeutics (antivirals, neutralising monoclonal antibodies and interleukin 6 inhibitors). 2023. Accessed March 6, 2023. Available from: https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/covid-therapeutics-antivirals-and-neutralising-monoclonal-antibodies\/."},{"key":"601_CR11","unstructured":"GOV.UK Coronavirus (COVID-19) in the UK. Testing in England. 2023. Accessed March 6, 2023. Available from: https:\/\/coronavirus.data.gov.uk\/details\/testing?areaType=nation&areaName=England."},{"key":"601_CR12","unstructured":"Italian National Institute of Health. COVID-19 integrated surveillance: key national data. 2023. Accessed March 6, 2023. Available from: https:\/\/www.epicentro.iss.it\/coronavirus\/sars-cov-2-sorveglianza-dati."},{"key":"601_CR13","unstructured":"European Centre for Disease Prevention and Control. Case definition for COVID-19, as of 3 December 2020. Accessed March 6, 2023. Available from: https:\/\/www.ecdc.europa.eu\/en\/covid-19\/surveillance\/case-definition."},{"key":"601_CR14","unstructured":"European Centre for Disease and Control and World Health Organization. Joint ECDC-WHO Regional Office for Europe Weekly COVID-19 Surveillance Bulletin. 2023. Accessed January 12, 2023. Available from: https:\/\/worldhealthorg.shinyapps.io\/euro-covid19\/."},{"issue":"10","key":"601_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1017\/ice.2016.117","volume":"37","author":"ML Schweizer","year":"2016","unstructured":"Schweizer ML, Braun BI, Milstone AM. Research methods in healthcare epidemiology and antimicrobial stewardship-quasi-experimental designs. Infect Control Hosp Epidemiol. 2016;37(10):1135\u201340. https:\/\/doi.org\/10.1017\/ice.2016.117.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"601_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","volume":"27","author":"AK Wagner","year":"2002","unstructured":"Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299\u2013309. https:\/\/doi.org\/10.1046\/j.1365-2710.2002.00430.x.","journal-title":"J Clin Pharm Ther"},{"issue":"6 Suppl","key":"601_CR17","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.acap.2013.08.002","volume":"13","author":"RB Penfold","year":"2013","unstructured":"Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr. 2013;13(6 Suppl):S38\u201344. https:\/\/doi.org\/10.1016\/j.acap.2013.08.002.","journal-title":"Acad Pediatr"},{"key":"601_CR18","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1136\/bmj.h2750","volume":"350","author":"E Kontopantelis","year":"2015","unstructured":"Kontopantelis E, Doran T, Springate DA, Buchan I, Reeves D. Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis. BMJ. 2015;350:2750. https:\/\/doi.org\/10.1136\/bmj.h2750.","journal-title":"BMJ"},{"issue":"24","key":"601_CR19","doi-asserted-by":"publisher","first-page":"13253","DOI":"10.3390\/ijerph182413253","volume":"18","author":"IC Antonazzo","year":"2021","unstructured":"Antonazzo IC, Fornari C, Maumus-Robert S, et al. Impact of COVID-19 Lockdown, during the two waves, on drug use and emergency department access in people with epilepsy: an interrupted time-series analysis. Int J Environ Res Public Health. 2021;18(24):13253. https:\/\/doi.org\/10.3390\/ijerph182413253.","journal-title":"Int J Environ Res Public Health"},{"key":"601_CR20","unstructured":"World Health Organization (WHO). Clinical management of COVID-19: living guideline, 15 September 2022. Accessed March 6, 2023. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2023.1."},{"issue":"12","key":"601_CR21","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.cmi.2022.08.013","volume":"28","author":"M Bartoletti","year":"2022","unstructured":"Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Martin-Quiros A, Pa\u00f1o-Pardo JR, Power N, Sibani M, Szabo BG, Tsiodras S, Zollner-Schwetz I, Rodr\u00edguez-Ba\u00f1o J. European Society of Clinical Microbiology and Infectious Diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild\/moderate disease. Clin Microbiol Infect. 2022;28(12):1578\u201390. https:\/\/doi.org\/10.1016\/j.cmi.2022.08.013.","journal-title":"Clin Microbiol Infect"},{"key":"601_CR22","unstructured":"U.S. Department of Health & Human Services. COVID-19 Therapeutics Thresholds, Orders, and Replenishment by Jurisdiction. 2023. Accessed March 6, 2023. Available from: https:\/\/aspr.hhs.gov\/COVID-19\/Therapeutics\/orders\/Pages\/default.aspx."},{"issue":"5","key":"601_CR23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMc2207519","volume":"387","author":"E Takashita","year":"2022","unstructured":"Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y. Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387(5):468\u201370. https:\/\/doi.org\/10.1056\/NEJMc2207519.","journal-title":"N Engl J Med."},{"key":"601_CR24","unstructured":"National Institute of health (NIH) COVID-19 Treatment Guidelines. Table 2a. Therapeutic Management of Non hospitalized Adults With COVID-19. 2022. Accessed March 6, 2023. Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/tables\/management-of-nonhospitalized-adults-summary\/."},{"issue":"8","key":"601_CR25","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/S1473-3099(22)00119-0","volume":"22","author":"R Dal-R\u00e9","year":"2022","unstructured":"Dal-R\u00e9 R, Becker SL, Bottieau E, Holm S. Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach. Lancet Infect Dis. 2022;22(8):e231\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(22)00119-0.","journal-title":"Lancet Infect Dis"},{"key":"601_CR26","unstructured":"Italian Medicines Agency (AIFA). Prescription of Paxlovid by the General Practitioner. 2022. Accessed March 6, 2023. Available from: https:\/\/www.aifa.gov.it\/en\/-\/prescrizione -paxlovid-mmg."},{"issue":"15","key":"601_CR27","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Sim\u00f3n-Campos A, Pypstra R, Rusnak JM. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397\u2013408. https:\/\/doi.org\/10.1056\/NEJMoa2118542.","journal-title":"N Engl J Med."},{"issue":"11","key":"601_CR28","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","volume":"22","author":"D Focosi","year":"2022","unstructured":"Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis. 2022;22(11):e311\u201326. https:\/\/doi.org\/10.1016\/S1473-3099(22)00311-5.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"601_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","volume":"21","author":"M Cox","year":"2023","unstructured":"Cox M, Peacock TP, Harvey WT, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol. 2023;21(2):112\u201324. https:\/\/doi.org\/10.1038\/s41579-022-00809-7.","journal-title":"Nat Rev Microbiol"},{"key":"601_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105252","volume":"198","author":"L Vangeel","year":"2022","unstructured":"Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198: 105252. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105252.","journal-title":"Antiviral Res"},{"key":"601_CR31","unstructured":"Italian Medicines Agency (AIFA). Monitoring of antivirals for COVID-19: new report published. 2022. Accessed March 6, 2023. Available from: https:\/\/www.aifa.gov.it\/en\/-\/monitoraggio-antivirali-per-covid-19-pubblicato-il-report-n.-21."},{"issue":"10371","key":"601_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0140-6736(22)02398-4","volume":"401","author":"H Tibble","year":"2023","unstructured":"Tibble H, Mueller T, Proud E, Hall E, Kurdi A, Robertson C, Bennie M, Woolford L, Sheikh A. Uptake of monoclonal antibodies and antiviral therapies for COVID-19 in Scotland. Lancet. 2023;401(10371):101\u20132. https:\/\/doi.org\/10.1016\/S0140-6736(22)02398-4.","journal-title":"Lancet"},{"key":"601_CR33","unstructured":"GOV.UK. Changes to COVID-19 testing in England from 1 April. 2022. Accessed March 6, 2023. Available from: https:\/\/www.gov.uk\/government\/news\/changes-to-covid-19-testing-in-england-from-1-april."},{"key":"601_CR34","doi-asserted-by":"publisher","unstructured":"Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial [published online ahead of print, 2022 Dec 22]. Lancet. 2022. doi:https:\/\/doi.org\/10.1016\/S0140-6736(22)02597-1","DOI":"10.1016\/S0140-6736(22)02597-1"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00601-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00601-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00601-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T14:17:50Z","timestamp":1692195470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00601-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["601"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00601-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,6]]},"assertion":[{"value":"20 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Verona within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gianluca Trifir\u00f2 has served in the past three years on advisory boards\/seminars funded by SANOFI, Eli Lilly, AstraZeneca, Abbvie, Servier, Mylan, Gilead and Amgen; he was the scientific director of a Master program on pharmacovigilance, pharmacoepidemiology and real-world evidence which has received non-conditional grant from various pharmaceutical companies; he coordinated a pharmacoepidemiology team at the University of Messina until October 2020, which has received funding for conducting observational studies from various pharmaceutical companies (Boehringer Ingelheim, Daichii Sankyo, PTC Pharmaceuticals). He is also scientific coordinator of the academic spin-off \u201cINSPIRE srl\u201d which has received funding for conducting observational studies from contract research organizations (RTI Health Solutions, Pharmo Institute N.V.). All the above-mentioned activities are not related to the topic of the manuscript. Mariam Molokhia has received grants previously from the International Serious Adverse Events Consortium, SAEC (not related to the topic of the manuscript). The other authors have no conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors contributed equally to this work.\u00a0All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}